CIK 0001662774 · Non-accelerated filer<br>Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 901024039
- Phone
- 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 70 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-24 | Senner Christopher J. Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2023-05-24 | RYAN UNA S Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2023-05-24 | McLoughlin Margaret Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2023-05-24 | Lamond David Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2023-05-24 | Bray June Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2023-03-06 | Monohon Ted Chief Accounting Officer & VP | Sale | −1,871 | $0.98 | $2K | 27,440 |
| 2023-02-01 | Thye Dirk Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +600,000 | 600,000 | ||
| 2023-02-01 | Smith Karen L. Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +225,000 | 225,000 | ||
| 2023-02-01 | Monohon Ted Chief Accounting Officer & VP | Grant or award · Employee Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2023-02-01 | Hannah Brendan Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +225,000 | 225,000 | ||
| 2022-12-05 | Monohon Ted Chief Accounting Officer & VP | Shares withheld for taxes | −1,640 | $0.72 | $1K | 29,311 |
| 2022-09-06 | Monohon Ted Chief Accounting Officer & VP | Shares withheld for taxes | −1,520 | $1.64 | $2K | 30,951 |
| 2022-06-29 | Monohon Ted Chief Accounting Officer & VP | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2022-06-09 | Bray June Director | Grant or award · Stock Option (right to buy) | +54,000 | 54,000 | ||
| 2022-06-08 | Senner Christopher J. Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2022-06-08 | RYAN UNA S Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2022-06-08 | Lamond David Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2022-06-08 | McLoughlin Margaret Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2022-06-06 | Monohon Ted Chief Accounting Officer & VP | Shares withheld for taxes | −1,529 | $3.12 | $5K | 32,471 |
| 2022-06-06 | Holsinger Leslie EVP, Preclinical Development | Shares withheld for taxes | −10,920 | $2.86 | $31K | 148,080 |
Page 6 of 8 · 149 trades